{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:17:08Z","timestamp":1787840228859,"version":"build-2784847793"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We propose a strategy to reduce unnecessary prostate biopsies in Chinese patients with total prostate-specific antigen (tPSA) &gt;10 ng ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    and Prostate Imaging Reporting and Data System (PI-RADS) scores between 1 and 3. Clinical data derived from 517 patients of The First Affiliated Hospital of USTC (Hefei, China) from January 2020 to December 2023 who met the screening criteria for the study were retrospectively collected. Independent predictors were identified via univariate and multivariate logistic regression analysis. The diagnostic capacity of clinical variables was evaluated using the receiver operating characteristic (ROC) curves and area under the curve (AUC). A prostate biopsy strategy was developed via risk stratification. Of the 517 patients, 17\/348 (4.9%) with PI-RADS 1\u20132 were diagnosed with clinically significant prostate cancer (csPCa), and 27\/169 (16.0%) patients with PI-RADS 3 were diagnosed with csPCa. The appropriate prostate-specific antigen density (PSAD) cut-off values were 0.45 ng ml\n                    <jats:sup>\u22122<\/jats:sup>\n                    for PI-RADS 1\u20132 patients and 0.3 ng ml\n                    <jats:sup>\u22122<\/jats:sup>\n                    for PI-RADS 3 patients. The appropriate prostate volume (PV) cut-off values were 40 ml for PI-RADS 1\u20132 patients and 50 ml for PI-RADS 3 patients. The prostate biopsy strategy based on PSAD and PV developed in this study can reduce unnecessary prostate biopsies in patients with tPSA &gt;10 ng ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    and PI-RADS 1\u20133. In the study, 66.5% (344\/517) patients did not need to undergo prostate biopsy, at the expense of missing only 1.7% (6\/344) patients with csPCa.\n                  <\/jats:p>","DOI":"10.4103\/aja202499","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T02:00:27Z","timestamp":1738029627000},"page":"531-536","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A strategy to reduce unnecessary prostate biopsies in patients with tPSA &gt;10 ng ml\u22121 and PI-RADS 1\u20133"],"prefix":"10.4103","volume":"27","author":[{"given":"Qi-Fei","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Department of Urology, Affiliated Provincial Hospital of Anhui Medical University, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Xun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Han","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Feng","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Department of Urology, Affiliated Provincial Hospital of Anhui Medical University, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"R1-20250716","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20250716","first-page":"47","article-title":"Cancer incidence and mortality in China,","volume":"4","author":"Han","year":"2022","journal-title":"J Natl Cancer Cent"},{"key":"R3-20250716","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-Isup-SIOG guidelines on prostate cancer-2024 update Part I:screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"R4-20250716","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21147\/j.issn.1000-9604.2019.01.04","article-title":"National Health Commission of the People's Republic of China. Chinese guidelines for diagnosis and treatment of prostate cancer 2018 (English version)","volume":"31","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"R5-20250716","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3322\/caac.20066","article-title":"American Cancer Society guideline for the early detection of prostate cancer:update 2010","volume":"60","author":"Wolf","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"R6-20250716","first-page":"29","article-title":"[China guideline for the screening and early detection of prostate cancer (2022, Beijing)","volume":"44","author":"He","year":"2022","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R7-20250716","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bju.13024","article-title":"Transperineal template-guided prostate biopsy:10 years of experience","volume":"117","author":"Mai","year":"2016","journal-title":"BJU Int"},{"key":"R8-20250716","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12957-017-1238-9","article-title":"Detection rate of prostate cancer following biopsy among the Northern Han Chinese population:a single-center retrospective study of 1022 cases","volume":"15","author":"Jia","year":"2017","journal-title":"World J Surg Oncol"},{"key":"R9-20250716","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41585-019-0212-4","article-title":"Multiparametric MRI for prostate cancer diagnosis:current status and future directions","volume":"17","author":"Stabile","year":"2020","journal-title":"Nat Rev Urol"},{"key":"R10-20250716","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System version 2.1:2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"R11-20250716","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bju.15277","article-title":"Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation","volume":"127","author":"Schoots","year":"2021","journal-title":"BJU Int"},{"key":"R12-20250716","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMe2214658","article-title":"Reducing prostate cancer overdiagnosis","volume":"387","author":"Gulati","year":"2022","journal-title":"N Engl J Med"},{"key":"R13-20250716","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","article-title":"Prostate Imaging Reporting and Data System 3 category cases at multiparametric magnetic resonance for prostate cancer:a systematic review and meta-analysis","volume":"6","author":"Maggi","year":"2020","journal-title":"Eur Urol Focus"},{"key":"R14-20250716","doi-asserted-by":"crossref","first-page":"1024204","DOI":"10.3389\/fonc.2022.1024204","article-title":"Combination of PI-RADS score and PSAD can improve the diagnostic accuracy of prostate cancer and reduce unnecessary prostate biopsies","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"R15-20250716","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (Isup) consensus conference on gleason grading of prostatic carcinoma:definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R16-20250716","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.22.00123","article-title":"Low-grade prostate cancer:time to stop calling it cancer","volume":"40","author":"Eggener","year":"2022","journal-title":"J Clin Oncol"},{"key":"R17-20250716","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves:a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"R18-20250716","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality:the CAP randomized clinical trial","volume":"319","author":"Martin","year":"2018","journal-title":"JAMA"},{"key":"R19-20250716","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"R20-20250716","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-specific antigen screening and 15-year prostate cancer mortality:a secondary analysis of the CAP randomized clinical trial","volume":"331","author":"Martin","year":"2024","journal-title":"JAMA"},{"key":"R21-20250716","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1370\/afm.2205","article-title":"Digital rectal examination for prostate cancer screening in primary care:a systematic review and meta-analysis","volume":"16","author":"Naji","year":"2018","journal-title":"Ann Fam Med"},{"key":"R22-20250716","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1002\/cam4.5100","article-title":"Development and external validation of a novel nomogram to predict prostate cancer in biopsy-na\u00efve patients with PSA <10 ng\/ml and PI-RADS v2.1 =3 lesions","volume":"12","author":"Hu","year":"2023","journal-title":"Cancer Med"},{"key":"R23-20250716","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.juro.2016.08.103","article-title":"Prostate specific antigen and prostate cancer in Chinese men undergoing initial prostate biopsies compared with western cohorts","volume":"197","author":"Chen","year":"2017","journal-title":"J Urol"},{"key":"R24-20250716","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bju.14049","article-title":"Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-na\u00efve men with suspicion of prostate cancer","volume":"122","author":"Hansen","year":"2018","journal-title":"BJU Int"},{"key":"R25-20250716","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.7150\/ijms.45730","article-title":"The prediction value of PI-RADS v2 score in high-grade prostate cancer:a multicenter retrospective study","volume":"17","author":"Chen","year":"2020","journal-title":"Int J Med Sci"},{"key":"R26-20250716","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in Asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat Rev Urol"},{"key":"R27-20250716","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.juro.2014.11.019","article-title":"The clinical and economic implications of specimen provenance complications in diagnostic prostate biopsies","volume":"193","author":"Wojno","year":"2015","journal-title":"J Urol"},{"key":"R28-20250716","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bju.16041","article-title":"Cancer detection and complications of transperineal prostate biopsy with antibiotics when indicated","volume":"132","author":"Boev\u00e9","year":"2023","journal-title":"BJU Int"},{"key":"R29-20250716","doi-asserted-by":"crossref","first-page":"e244258","DOI":"10.1001\/jamanetworkopen.2024.4258","article-title":"Magnetic resonance imaging, clinical, and biopsy findings in suspected prostate cancer:a systematic review and meta-analysis","volume":"7","author":"Haj-Mirzaian","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R30-20250716","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.3390\/diagnostics13162677","article-title":"The impact of prostate volume on the Prostate Imaging and Reporting Data System (PI-RADS) in a real-world setting","volume":"13","author":"Volz","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R31-20250716","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/aja.2012.28","article-title":"External validation of the prostate cancer prevention trial and the European randomized study of screening for prostate cancer risk calculators in a Chinese cohort","volume":"14","author":"Zhu","year":"2012","journal-title":"Asian J Androl"},{"key":"R32-20250716","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1007\/s00330-020-06725-9","article-title":"Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes","volume":"30","author":"Abreu-Gomez","year":"2020","journal-title":"Eur Radiol"},{"key":"R33-20250716","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2967\/jnumed.123.266742","article-title":"The value of 68Ga-PSMA PET\/MRI for classifying patients with PI-RADS 3 lesions on multiparametric MRI:a prospective single-center study","volume":"65","author":"Shi","year":"2024","journal-title":"J Nucl Med"},{"key":"R34-20250716","doi-asserted-by":"crossref","first-page":"674","DOI":"10.4103\/aja20239","article-title":"The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men","volume":"25","author":"Chiu","year":"2023","journal-title":"Asian J Androl"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:17:39Z","timestamp":1787836659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/aja202499","relation":{},"ISSN":["1745-7262","1008-682X"],"issn-type":[{"value":"1745-7262","type":"print"},{"value":"1008-682X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"2024-06-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}